The companies expect the new AI solution to facilitate quick and informed diagnosis. Credit: Seanbatty from Pixabay.

Medical imaging solutions firm Guerbet has partnered with IBM Watson Health to develop and commercialise an artificial intelligence (AI)-based solution to diagnose prostate cancer.

Furthermore, the medical imaging technology will help stratify, characterise and monitor lesions over time. The companies expect the AI solution to facilitate quick and informed diagnoses.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Statistics reveal more than 10% increase in MRIs each year for prostate cancer, the most commonly identified cancer type in men.

According to a previous Lancet clinical study, 27% of biopsies could be avoided, with the identification of 18% unseen cancers using multiparameter MRI.

IBM Watson Health Imaging chief medical officer David Gruen said: “The main diagnostic challenge with prostate cancer lies in identifying cancers requiring rapid treatment and those requiring only active surveillance, while avoiding unnecessary biopsies.

“For this reason, optimal patient outcomes depend on the rapid and accurate diagnosis and treatments that AI technologies can potentially help provide.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The AI solution will leverage Watson image analysis to support the diagnosis and clinical decisions of radiologists and oncologists.

It will be designed for use with the majority of the Picture Archiving and Communication System (PACS) visualisation systems, allowing direct and easy integration into healthcare workflows.

Guerbet CEO Yves L’Epine said: “Some prostate cancers warrant active therapeutic management while others require only regular monitoring.

“Augmented intelligence can help enable doctors to diagnose these different cases more rapidly and more accurately, thus helping to potentially reduce the number of unnecessary biopsies and allowing them to propose the most appropriate therapeutic strategy for each patient.”

Guerbet and IBM Watson Health previously formed an alliance in July last year for an AI programme to diagnose and monitor liver cancer.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact